Published in Breast Cancer (Dove Med Press) on December 21, 2015
Circulating Phospholipids as Biomarkers of Breast Cancer: A Review. Breast Cancer (Auckl) (2016) 0.75
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med (2000) 25.49
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med (2002) 18.61
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med (1997) 10.83
Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet (1999) 8.44
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol (2011) 7.10
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst (1999) 6.48
Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst (2005) 5.65
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA (2013) 4.82
Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med (2015) 4.77
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (2015) 4.58
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin (2003) 4.43
Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. J Natl Cancer Inst (2014) 4.05
High constant incidence in twins and other relatives of women with breast cancer. Nat Genet (2000) 4.03
Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 3.92
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys (2009) 3.91
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol (2008) 3.68
Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol (2006) 3.62
Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol (2006) 3.15
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol (2014) 3.15
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet (2015) 3.02
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol (2011) 3.02
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat (2008) 2.97
The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer (2008) 2.91
Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst (2003) 2.84
Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol (1994) 2.77
Breast cancer before age 40 years. Semin Oncol (2009) 2.71
ACOG Committee Opinion. Number 299, September 2004 (replaces No. 158, September 1995). Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol (2004) 2.69
The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol (2007) 2.40
Breast cancer in young women: poor survival despite intensive treatment. PLoS One (2009) 2.36
Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol (2013) 2.35
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol (2008) 2.28
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol (2014) 2.25
The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys (1994) 2.17
The relationship of mammographic density and age: implications for breast cancer screening. AJR Am J Roentgenol (2012) 2.15
Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg (2009) 2.14
Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol (2012) 2.08
US breast cancer mortality trends in young women according to race. Cancer (2014) 2.07
Pregnancy after treatment of breast cancer--a population-based study on behalf of Danish Breast Cancer Cooperative Group. Acta Oncol (2008) 1.95
Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol (2014) 1.93
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol (2014) 1.92
Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. JAMA (2014) 1.91
Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys (2010) 1.76
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol (2003) 1.75
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol (2015) 1.73
Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. J Clin Oncol (2007) 1.62
Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer (2004) 1.62
Breast carcinomas occurring in young women (< 35 years) are different. Br J Cancer (1996) 1.57
Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer (2001) 1.57
Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res (2012) 1.55
Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer (2006) 1.54
Fertility preservation in women. Nat Rev Endocrinol (2013) 1.50
Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol (2005) 1.48
Amenorrhea from breast cancer therapy--not a matter of dose. N Engl J Med (2010) 1.40
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer (2011) 1.36
Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg Oncol (2012) 1.35
Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat (2009) 1.33
Does nipple preservation in mastectomy improve satisfaction with cosmetic results, psychological adjustment, body image and sexuality? Breast Cancer Res Treat (2008) 1.33
Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat (2011) 1.29
Breast cancer in young women: clinicopathological features and biological specificity. Breast (2003) 1.25
BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer (2006) 1.24
The American Brachytherapy Society consensus statement for accelerated partial breast irradiation. Brachytherapy (2013) 1.23
Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril (2011) 1.23
Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res (2012) 1.21
Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer (2010) 1.20
Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer (2005) 1.19
The effect of age on delay in diagnosis and stage of breast cancer. Oncologist (2012) 1.15
Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study. J Natl Cancer Inst (2013) 1.13
Breast cancer in women aged 30 and under. Cancer (1982) 1.13
Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol (1999) 1.13
Breast cancer diagnosis in women < or = 40 versus 50 to 60 years: increasing size and stage disparity compared with older women over time. Ann Surg Oncol (2006) 1.10
Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genet Med (2014) 1.10
Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer (2004) 1.04
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer (2011) 1.04
Options on fertility preservation in female cancer patients. Cancer Treat Rev (2011) 0.99
Radiation dose to conceptus resulting from tangential breast irradiation. Int J Radiat Oncol Biol Phys (2003) 0.99
Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups. Ann Oncol (2009) 0.99
Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol (2004) 0.98
Long-Term Psychosocial Functioning in Women with Bilateral Prophylactic Mastectomy: Does Preservation of the Nipple-Areolar Complex Make a Difference? Ann Surg Oncol (2015) 0.97
Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time? Breast Cancer Res Treat (2014) 0.96